(Q37739997)

22 August 2017

1 reference

retracted paper

2 references

Dataset for "Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine"

Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine

title

Early years of biological agents therapy in Crohn's disease and risk of the human polyomavirus JC reactivation (English)

1 reference

22 August 2017

0 references

human polyomavirus

1 reference

Valeria Pietropaolo

8

0 references

Elena Anzivino

series ordinal

6

object named as

Elena Anzivino

1 reference

22 August 2017

1

Anna Bellizzi

1 reference

22 August 2017

5

Monica Mischitelli

1 reference

22 August 2017

3

Daniela Fioriti

1 reference

22 August 2017

Valentina Barucca

2

1 reference

22 August 2017

Maria T Colosimo

series ordinal

4

1 reference

22 August 2017

Fernanda Chiarini

series ordinal

7

1 reference

22 August 2017

publication date

1 August 2010

1 reference

Journal of Cellular Physiology

22 August 2017

published in

1 reference

22 August 2017

volume

224

1 reference

22 August 2017

issue

2

1 reference

22 August 2017

page(s)

316-326

1 reference

Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis.

22 August 2017

cites work

1 reference

JC virus DNA load in patients with and without progressive multifocal leukoencephalopathy

21 January 2018

1 reference

Recent trends in the epidemiology of inflammatory bowel diseases: up or down?

21 January 2018

1 reference

Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain

21 January 2018

1 reference

Host innate defenses in the lung: the role of cytokines

21 January 2018

1 reference

CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study

21 January 2018

1 reference

Two cases of progressive multifocal leukoencephalopathy after allogeneic hematopoietic cell transplantation and a review of the literature

21 January 2018

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Infliximab for the treatment of fistulas in patients with Crohn's disease

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Anti-tumor necrosis factor alpha therapy and the risk of JC virus infection

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

JC virus viremia in interferon-beta -treated and untreated Italian multiple sclerosis patients and healthy controls

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

The immune response in inflammatory bowel disease

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

No excess risk for colorectal cancer among subjects seropositive for the JC polyomavirus

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Review article: targeting TNF alpha as a key cytokine in the inflammatory processes of Crohn's disease--the mechanisms of action of infliximab

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Antineutrophil cytoplasmic antibodies in children with inflammatory bowel disease: prevalence and diagnostic value

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Functional variants of OCTN cation transporter genes are associated with Crohn disease

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Therapeutic monoclonal antibodies

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Another anti-TNF therapy for patients with Crohn's disease

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Immunopathogenesis of delayed-type hypersensitivity

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Review article: mild to moderate Crohn's disease--defining the basis for a new treatment algorithm

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Real-time quantitative PCR assays for detection and monitoring of pathogenic human viruses in immunosuppressed pediatric patients.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Recent developments in the immunology of inflammatory bowel disease

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Infliximab maintenance therapy for fistulizing Crohn's disease

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Transcending conventional therapies: the role of biologic and other novel therapies

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Regulation of inflammation

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Anti-interleukin-12 antibody for active Crohn's disease

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Lymphocyte homing and homeostasis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Biologic therapy of inflammatory bowel disease.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national patient register

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

A population-based case control study of potential risk factors for IBD.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Treatment of severe Crohn's disease with anti-CD4 monoclonal antibody.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Quantitative real-time PCR assay for detection of human polyomavirus infection

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Natalizumab for active Crohn's disease

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

RDP58, a novel immunomodulatory peptide with anti-inflammatory effects. A pharmacological study in trinitrobenzene sulphonic acid colitis and Crohn disease

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Transmission of CARD15 (NOD2) variants within families of patients with inflammatory bowel disease

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

AIDS- and non-AIDS-related PML association with distinct p53 polymorphism

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Certolizumab pegol for the treatment of Crohn's disease

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Molecular biology and immunoregulation of human neurotropic JC virus in CNS.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

The Dynamics of Herpesvirus and Polyomavirus Reactivation and Shedding in Healthy Adults: A 14‐Month Longitudinal Study

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Epidemiology of inflammatory bowel disease

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Taming TNF: strategies to restrain this proinflammatory cytokine

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Presidential address: Gastrointestinal illness and the biopsychosocial model

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Infliximab-induced lupus in Crohn's disease: a case report.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

JC virus: an oncogenic virus in animals and humans?

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Immunotherapy of Crohn's disease

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Natalizumab and immune cells

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Reactivation of JC virus and development of PML in patients with multiple sclerosis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

General principles of medical therapy of inflammatory bowel disease

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Treatment of murine colitis by Lactococcus lactis secreting interleukin-10.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Revisiting the role of tumor necrosis factor alpha and the response to surgical injury and inflammation

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Critical role of the CD40 CD40-ligand pathway in regulating mucosal inflammation-driven angiogenesis in inflammatory bowel disease

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

NOD2/CARD15 mutation analysis and genotype-phenotype correlation in Jewish pediatric patients compared with adults with Crohn's disease

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Inflammatory bowel disease: new insights into pathogenesis and treatment

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Biologics in inflammatory bowel disease: how much progress have we made?

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Frequency and phenotype of JC virus-specific CD8+ T lymphocytes in the peripheral blood of patients with progressive multifocal leukoencephalopathy

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Prevalence, predictors, and clinical consequences of medical adherence in IBD: how to improve it?

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Impact of biologic agents on infectious diseases

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Presence of JC virus-specific CTL in the cerebrospinal fluid of PML patients: rationale for immune-based therapeutic strategies

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Polyomavirus JC infects human brain microvascular endothelial cells independent of serotonin receptor 2A.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name?

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Azathioprine for maintaining remission of Crohn's disease

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Evolving paradigms in the pathogenesis of IBD.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Infliximab in the treatment of medically refractory indeterminate colitis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Increased expression of interleukin 17 in inflammatory bowel disease

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Clinical aspects and pathophysiology of inflammatory bowel disease

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Polyomavirus infection in pediatric renal transplant recipients: evaluation using a quantitative real-time PCR technique

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

IL-17 family cytokines and the expanding diversity of effector T cell lineages

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Maintenance therapy with certolizumab pegol for Crohn's disease

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Onercept for Moderate-to-Severe Crohn’s Disease: A Randomized, Double-Blind, Placebo-Controlled Trial

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy?

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Regulation of gene expression in primate polyomaviruses

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Role of cytokines in the pathogenesis of inflammatory bowel disease

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Inflammatory bowel disease, gut bacteria and probiotic therapy

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Treatment of luminal and fistulizing Crohn's disease with infliximab

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Human polyomaviruses DNA detection in peripheral blood leukocytes from immunocompetent and immunocompromised individuals.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Medical therapy for inflammatory bowel disease

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/JCP.22146

Identifiers

DOI

10.1002/JCP.22146

1 reference

22 August 2017

1 reference